Blood test may predict chemo failure in aggressive breast cancer

NCT ID NCT04771871

Recruiting now Knowledge-focused Sponsor: University College Hospital, Ibadan Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how well standard chemotherapy works in people with triple-negative breast cancer, an aggressive type that lacks targeted treatments. Researchers will also measure tiny molecules called microRNAs and tumor DNA in the blood to see if changes can signal when the drugs stop working. The goal is to find a simple blood test that helps doctors adjust treatment early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin (chemotherapy drugs)
What this could lead to: If successful, this could lead to a simple blood test that tells doctors early when chemotherapy is not working, allowing them to switch treatments sooner.
What could go wrong: This is a small, early-phase study with only 42 people. The blood test idea is still experimental and may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Neoplastic Cells, Circulating triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Lagos State University Teaching Hospital
NOT_YET_RECRUITING

Lagos, Nigeria
Lagos University Teaching Hospital
NOT_YET_RECRUITING

Lagos, Nigeria
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITING

Ile-Ife, Oshun, Nigeria
University College Hospital
RECRUITING

Ibadan, Oyo State, 200221, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.